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Abstract
Background: Abnormalities in tumor suppressors p14, p16 and p53 are reported in several human cancers. In
ovarian epithelial carcinogenesis, p16 and p53 show higher immunohistochemical staining frequencies in malignant
tumors and are associated with poor prognoses. p14 was only analyzed in carcinomas, with conflicting results.
There are no reports on its expression in benign and borderline tumors. This study aims to determine p14, p16 and
p53 expression frequencies in ovarian benign, borderline and malignant tumors and their associations with clinical
parameters.
Methods: A cross-sectional study utilizing immunohistochemistry was performed on paraffin-embedded ovarian
epithelial tumor samples. Clinical data were collected from medical records. Fisher’s exact test and the Bonferroni
correction were performed for frequency associations. Survival comparisons utilized Kaplan-Meier and log rank
testing. Associations were considered significant when p < 0.05.
Results: p14 absent expression was associated with malignant tumors (60 % positive) (p = 0.000), while 93 % and
94 % of benign and borderline tumors, respectively, were positive. p16 was positive in 94.6 % of carcinomas, 75 %
of borderline and 45.7 % of benign tumors (p = 0.000). p53 negative staining was associated with benign tumors (2.9 %
positive) (p = 0.016) but no difference was observed between borderline (16.7 %) and malignant tumors (29.7 %)
(p = 0.560). No associations were found between expression rates, disease-free survival times or clinical variables.
Carcinoma subtypes showed no difference in expression.
Conclusions: This is the first description of p14 expression in benign and borderline tumors. It remains stable in
benign and borderline tumors, while carcinomas show a significant absence of staining. This may indicate that p14
abnormalities occur later in carcinogenesis. p16 and p53 frequencies increase from benign to borderline and malignant
tumors, similarly to previous reports, possibly reflecting the accumulation of inactive mutant protein. The small sample
size may have prevented statistically significant survival analyses and clinical correlations. Future studies should
investigate genetic abnormalities in p14 coding sequences and include all types of ovarian epithelial tumors. Bigger
sample sizes may be needed for significant associations.
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Background
Ovarian cancer has the seventh highest cancer incidence
in women worldwide. In 2012, 238,719 new cases were
diagnosed and 151,917 women died from the disease [1].
Malignant epithelial tumors comprise 90 % of all ovarian
cancers and are usually diagnosed at advanced stages,
leading to high mortality and low survival rates [2, 3].
Abnormalities in cell cycle control have been reported in
a wide range of human cancers [4, 5]. The eukaryotic
cell cycle is divided in five phases: mitosis, gap 0 (G0)
gap 1 (G1), synthesis (S) and gap 2 (G2). Most human
adult cells are in G0, with no increase in cell size or
DNA content. This state is maintained by tumor sup-
pressor protein pRb. When external growth factors are
present, the cell enters the G1 phase, during which there
is duplication of all cellular components, except DNA.
This is possible due to the release of the suppressing ef-
fects of pRb through the action of complexes formed by
cyclins and cyclin-dependent kinases. The inactivation of
pRb allows progression through G1 and into the synthe-
sis phase, when DNA is replicated. When DNA damage,
insufficient cell size or oncogenic stimuli are present,
other tumor suppressor proteins are activated and pre-
vent passage from G1 to S. If abnormalities are present
in these proteins, mutated cells can proliferate unre-
strictedly and generate a neoplasm [6–8]. Tumor sup-
pressors’ genetic and immunohistochemical alterations
are a common finding in human cancers, including ovar-
ian epithelial tumors, specially carcinomas [9–16]. In
this study, we focus on three of these proteins: p14, p16
and p53.
p14 (also known as ARF) is transcribed from the
CDKN2A gene. It sequesters MDM2 in the nucleolus,
preventing p53 degradation. Additionally, it inhibits
transcription factor E2F activity. These actions lead to
cell cycle arrest [17, 18]. Previous studies about p14 im-
munohistochemical expression in ovarian epithelial tu-
mors have focused only on carcinomas and display
conflicting results. Saegusa et al. described positivity in
all carcinomas [19]. Hashiguchi et al. reported positivity
in 89.1 % of all carcinomas, while Khouja et al. found
that 89 % of carcinomas were negative [20, 21]. None of
these studies demonstrated any association with clinical
parameters or prognosis. We found no reports on p14
expression in benign and borderline tumors.
p16 is also a product of CDKN2A. It prevents cell
cycle advance by inhibiting cyclin D-cdk4/6, thus main-
taining pRb’s negative control over the restriction point
[10]. p16 is suppressed by pRb, and high expression of
p16 is associated with loss of pRb function, one of the
most common abnormalities in cancer [22]. Higher ex-
pression rates are found in carcinomas, followed by bor-
derline and benign tumors, despite a wide staining
percentage variation among studies [15, 23]. Some
authors report differences between high-grade serous
carcinoma (HGSC) and low-grade serous carcinoma
(LGSC), with the latter not differing from serous border-
line tumors. However, other studies show no difference
between HGSC and LGSC [16, 24–27]. When evaluated
as prognostic factors, both high and low levels of p16
staining have been linked to worse outcomes, while
intermediate levels were associated with longer sur-
vival times. Other reports found no association with
survival [23, 25–27]. In relation to epithelial types,
serous tumors show high expression, while mucinous
and endometrioid tumors demonstrate low levels or
absent staining [25, 28, 29].
p53 can arrest cell cycle progression or activate the
apoptosis pathway if DNA damage is extensive. In un-
altered cells, p53 is constantly degraded by MDM2, lead-
ing to a very short half-life. When DNA damage is
present, several factors (such as p14) cause MDM2
phosphorylation. p53 is stabilized and cellular levels rise,
serving as a transcription factor for some genes and
repressing others [6]. Mutations in TP53 are a common
event in most human cancers, transcribing inactive pro-
teins, which are resistant to degradation and detectable
by immunohistochemistry [22]. Ovarian carcinomas ex-
hibit the highest rates of expression in comparison to
borderline and benign tumors. Among carcinoma sub-
types, HGSC are more often positive than LGSC, mucin-
ous, endometrioid and clear cell carcinomas [15, 30, 31].
O’Neill et al. reported a high level of expression in 64 %
of HGSC and 18 % of LGSC [24]. Some reports indi-
cated that high levels of expression relate to poor prog-
nosis, but others found no association [15, 30]. In this
study, we aimed to assess p14, p16 and p53 expression
in ovarian epithelial tumors and to determine associa-
tions with disease-free survival time and clinical
variables.
Results
Mean age of diagnosis was 49.36 (45.68–53.03) for be-
nign tumors, 44.25 (38.24–50.26) for borderline tumors
and 58.35 (54.39–62.32) for malignant tumors (95 %
confidence interval). Malignant tumors were associated
with older age, while benign and borderline tumors
showed no statistical difference (p = 0.048). FIGO stage
information was available in 17.5 % of cases and no sta-
tistically significant associations were found. The highest
rates of p14 immunoreactivity were found in benign tu-
mors, decreasing in borderline tumors and even further
in carcinomas, as shown in Table 1. When considered
positive (score 1 or higher) or negative, 93 % of benign,
94 % of borderline and 60 % of malignant tumors were
positive (Fig. 1). Absent expression was associated with
carcinomas when compared to borderline and benign
tumors (p = 0.000), but no difference was observed
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between the last two (p = 1.000). Serous and mucinous
tumors demonstrated no difference in expression
(85.1 % and 89.7 %, respectively) (p = 1.000). Endome-
trioid tumors were significantly associated with negative
expression (all tumors were negative) (p = 0.000).
p16 expression was higher in malignant tumors, de-
creasing in borderline and benign tumors (Table 2). No
borderline or malignant tumor showed less than 11 %
positive nuclei. Positivity (score 3) was found in 94.6 %
of carcinomas, 75 % of borderline and 45.7 % of benign
tumors (Fig. 1). The different rates among all three types
were statistically significant (p = 0.000). 71.3 % of serous,
48.7 % of mucinous and 100 % of endometrioid tumors
were positive, but only serous and mucinous tumors
were statistically different (p = 0.034).
p53 staining was higher in malignant tumors, decreas-
ing in borderline and in benign tumors. No benign or
borderline tumor exhibited more than 50 % positive nu-
clei (Table 3). 29.7 % of malignant, 16.7 % of borderline
and 2.9 % of benign tumors were positive (score 2 or 3)
(Fig. 1). The rate difference was significant between be-
nign and borderline (p = 0.016), benign and malignant
tumors (p = 0.000), but not between borderline and ma-
lignant tumors (p = 0.560). 66.7 % of endometrioid,
12.8 % of mucinous and 11.9 % of serous tumors were
positive. Statistical significance was demonstrated
between endometrioid and serous tumors (p = 0.017).
No antibody showed expression differences among car-
cinoma subtypes. No correlations were found when
comparing expression rates between each other. We did
not encounter associations with disease-free survival
times or other clinical parameters.
Discussion
The main limitation of the study was its small sample
size. We believe this prevented statistically significant as-
sociations between immunohistochemical expression
and disease-free survival and clinical data. Our main
finding was the determination of p14 levels in benign
and borderline tumors and their difference in relation to
carcinomas. To our knowledge, no other study has in-
vestigated p14 in these tumors. 93 % and 94 % of benign
and borderline tumors, respectively, were positive. Car-
cinomas showed a significant absent expression, as re-
ported by Khouja et al. and Havrilesky et al. [21, 22].
Khouja et al. also reported no expression in normal
ovaries (n = 10). The high expression levels in benign
and borderline tumors may indicate wild-type p14 is not
detectable, with p14 mutation occurring early in ovarian
carcinogenesis. This would lead to mutant proteins, un-
responsive to negative feedback mechanisms, detectable
by immunohistochemistry. In laryngeal cancer, normal
tissue shows low levels (25 %), while dysplastic (82 %) and
neoplastic (100 %) tissues are mostly positive [32, 33].
Subsequent mutations could lead to loss of function and a
corresponding diminished expression in carcinomas. An-
other possible explanation for the progressive increase in
p14 expression is that its activity is maintained throughout
carcinogenesis, being overexpressed in response to onco-
genic signals. A mutation, loss of function and expression
Table 1 p14 expression in benign, borderline and malignant
tumors
PPN(a) Benign Borderline Malignant
0 7.1 % 5.6 % 40.5 %
1–10 5.7 % 25 % 18.9 %
11–50 47.1 % 66.7 % 35.1 %
51–100 40 % 2.8 % 5.4 %
(a) Percentage of positive nuclei
Fig. 1 Percentage of p14, p16 and p53 positive tumors in benign,
borderline and malignant tumors
Table 2 p16 expression in benign, borderline and malignant
tumors
PPN (a) Benign Borderline Malignant
0 1.4 % 0 % 0 %
1–10 14.4 % 0 % 0 %
11–50 38.6 % 25 % 5.4 %
51–100 45.7 % 75 % 94.6 %
(a) Percentage of positive nuclei
Table 3 p53 expression in benign, borderline and malignant
tumors
PPN (a) Benign Borderline Malignant
0 92.9 % 63.9 % 64.9 %
1–10 4.3 % 19.4 % 5.4 %
11–50 2.9 % 16.7 % 18.9 %
51–100 0 % 0 % 10.8 %
(a) Percentage of positive nuclei
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would be late events. This has been proposed in endomet-
rial carcinogenesis, where adenocarcinomas show greater
expression than normal endometrium, but high-grade tu-
mors are associated with absent staining [12]. In renal cell
carcinoma, El-Mokadem et al. [34] reported lower expres-
sion in neoplastic tissue when compared to normal kidney
samples.
p16 levels were similar to previous reports: carcinomas
are the most positive, followed by borderline tumors and
adenomas [23, 24]. 94.6 % of carcinomas were positive,
comparable to reports by Dong et al. and Kommoss et
al. [23, 26]. There is no consensus on interpretation
methods or cutoff values for positivity, leading to a wide
range of expression rates. Different clones also influence
this variation [21, 25]. The progressive increase in ex-
pression was also reported in normal mammary tissue
and breast carcinomas [13]. Possible explanations in-
clude: progressive loss of pRb function and its repressive
effect over p16; bypassing of p16’s tumor suppressing ef-
fect by alterations in other components of cell cycle con-
trol, leading to overexpression in an attempt to maintain
the control over cellular proliferation; accumulation of
inactive mutant proteins [10, 14, 22, 35]. We could not
find differences in expression among carcinoma sub-
types. However, p16 levels were statistically different be-
tween carcinomas and borderline tumors. Given that
most carcinomas were high grade, this finding may cor-
roborate the assumption that HGSC pathogenesis is in-
dependent from benign and borderline tumors [35].
High p16 levels were associated with serous histology, as
previously described by Dong et al. and O’Neill et al.
[23, 24]. There was no association between p16 and p14
levels. Despite being transcribed from the same locus, they
differ in exon 1. Mutations and methylations were re-
ported in their shared and unique sequences, explaining
why they display non-related expressions [11, 20, 36, 37].
p53 expression increased from benign to borderline
and malignant tumors, as previously reported [30].
Analogously to p14 and p16, reports on p53 expression
have different designs, interpretation methods and defi-
nitions of positive or negative. Expression rates vary ac-
cording to the clone utilized. As reported by Kmet et al.
[30], the most commonly used clones show a prevalence
of more than 50 % positivity in carcinomas. In our sam-
ple, 29.7 % of carcinomas were positive, a similar result
to another study using the same antibody (PAb240). The
gradual increase in p53 expression is explained by differ-
ent half-lives between the wild-type protein (constantly
degraded, short half-life) and mutant p53 (resistant to
degradation, long half-life). While the former is rarely
detectable, the latter accumulates in the cell and is more
likely to be detected immunohistochemically [9]. It has
been proposed that wild-type p53 inhibits p16 expres-
sion. Despite not showing statistical association, both
staining percentages increased in a similar manner,
which is compatible with this theory [21, 22]. The ma-
jority of authors report significant differences between
HGSC and LGSC or serous borderline tumors [19, 31].
We did not find a statistically significant difference be-
tween borderline and malignant tumors or among car-
cinoma types. Endometrioid tumors were statistically
associated with negative p14 (p = 0.04) and positive p53
(p = 0.047). While p < 0.05, we do not believe this is a
valid association, given that all our endometrioid sample
was composed of carcinomas, which are associated with
low p14 and high p53 staining.
Conclusions
We have demonstrated that p14 is positive in benign
and borderline tumors, while absent staining is associ-
ated with carcinomas. As observed in other organs, this
may indicate that loss of p14 activity is a late event in
tumorigenesis [33, 38]. Expression in normal ovaries has
been reported as absent, but this was based on a small
(n = 10) sample [21]. Further studies are necessary to de-
termine staining levels in non-neoplastic ovarian tissue.
We did not find associations between staining indexes
and disease-free survival times or clinical parameters.
Even though previous studies showed no prognostic
relevance, we believe larger samples are necessary to de-
termine if p14 has any unreported associations. p14 is
not as extensively studied in ovarian tumors as p16, and
reports on mutations and methylations of CDKN2A
rarely specify if these abnormalities affect their shared or
individual exons [11, 20, 36, 37]. Future studies should
report not only the presence of these alterations, but
also their location in CDKN2A. Additionally, they
should include benign and borderline tumors.
Methods
Sample selection
This is a cross-sectional study using buffered, 10 %
formalin-fixed, paraffin-embedded tissue samples from
women who underwent surgery for primary ovarian epi-
thelial tumors at Hospital de Clinicas de Porto Alegre
between January 2007 and January 2014. Clinical infor-
mation (age, FIGO stage, surgical findings, oral contra-
ceptive use, parity and family history of ovarian or breast
cancer) and disease-free times (defined as the number of
months from diagnosis to recurrence or death) were col-
lected from medical records. The original hematoxylin
and eosin stained slides were reviewed and one paraffin
block was selected from each case. We excluded possible
metastatic tumors, samples with insufficient epithelium
for immunohistochemical staining and those with undif-
ferentiated histology. Brenner tumors were not included
due to their rarity in our archives. The final sample con-
tained 143 tumors: 47 serous cystadenomas, 23 mucinous
Cabral et al. Journal of Ovarian Research  (2016) 9:69 Page 4 of 7
cystadenomas, 24 serous borderline tumors, 12 mucinous
borderline tumors, 4 low-grade serous carcinomas, 25
high-grade serous carcinomas, 5 mucinous carcinomas
and 3 endometrioid carcinomas.
Immunohistochemistry
Whole tissue sections were cut 3 μm thick and mounted
on silanized slides. Slides were incubated at 80 °C for
60 min, depariffinized and rehydrated. Water-bath antigen
retrieval was performed at 95 °C for 60 min, utilizing cit-
rate buffer ph 6.0. Endogenous peroxidase activity was
blocked with 3 % hydrogen peroxide in methanol solution
for 30 min. Slides were incubated overnight at 4 °C with
the following primary antibodies: anti-p14 (1:25, ab3642,
abcam®), anti-p16 (1:400, ab54210, abcam®) and anti-p53
(1:100, ab26, abcam®). ADVANCE™ (Dako) was used for
secondary antibody incubation, followed by hematoxylin
counterstaining and mounting. Positive and negative con-
trols for each antibody were also stained.
Immunohistochemical expression was assessed indi-
vidually by two pathologists. A third pathologist reviewed
conflicting results and a final score was reached. Due to
excessive background staining and previous reports about
the lack of specificity of cytoplasmic expression, only un-
equivocal nuclear positivity was considered valid [19].
Each tissue section was read in its entirety and a score
was assigned according to the percentage of positive nu-
clei in neoplastic epithelial cells: 0 (0 %), 1 (1–10 %), 2
(11–50 %) or 3 (51–100 %) (Fig. 2). Based on previous
studies, for p14, scores 1 or greater were considered posi-
tive [21]. For p16, only score 3 and for p53, scores 2 and 3
were taken as positive [16].
Statistical analysis
IBM SPSS Statistics version 22.0 (IBM Corporation,
2013) was used for all statistical calculations. Expression
of p14, p16 and p53 and their association with other
parameters were evaluated by Fisher’s exact test and the
Bonferroni correction. For disease-free survival analyses,
we used Kaplan-Meier’s estimate and the log-rank test.
95 % confidence interval for the mean age of patients at
diagnosis was submitted to post-hoc analysis (ANOVA
and Tukey’s range test). Associations were considered
statistically significant when p < 0.05.
Abbreviations
G0: Gap 0; G1: Gap 1; G2: Gap 2; HGSC: High-grade serous carcinoma;
LGSC: Low-grade serous carcinoma; PPN: Percentage of positive nuclei;
S: Synthesis
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